MEETING THE CHALLENGE OF PAIN MANAGEMENT

IN AN EVER-EVOLVING OPIOID EPIDEMIC

RPC ID: EG-001034

 

FRONT MATTER INTRODUCTION FOR LEARNERS

 

 

LAUNCH DATE/EXPIRATION DATE

This activity was initially launched on December 3, 2021 and will expire on March 31, 2023.

 

TARGET AUDIENCE

The primary audience for this initiative will be all providers eligible to prescribe opioid analgesics. A secondary audience includes non-prescribers involved in the care of patients receiving opioid analgesic therapy, nonpharmacologic therapies, and non-opioid medication therapies for the management of pain, including physicians, dentists and oral surgeons, residents and fellows, physician assistants, nurse practitioners, pharmacists, and registered nurses.

 

LEARNING OBJECTIVES

Module 1: The Epidemiology of Pain

Describe the scope and burden of chronic pain and opioid use disorder (OUD) in the United States

Explain the four phases of the overdose epidemic and its convergence with the COVID-19 pandemic

Module 2: Assessment of Pain and Initiation of Treatment

Assess patients in pain and set goals for pain management and functionality

Evaluate the range of therapeutic options for managing pain, including nonpharmacologic approaches and pharmacologic therapies (non-opioid and opioid analgesics)

Module 3: Acute Pain Management

Integrate opioid analgesics into an acute pain treatment plan individualized to the needs of the patient

Counsel patients and caregivers about the use of naloxone for opioid overdose

Module 4: Chronic Pain Management

Safely and effectively manage patients on opioid analgesics for the treatment of chronic pain

Analyze potential benefits with the risks of serious adverse outcomes when initiating, titrating, and discontinuing use of opioids

Module 5: Prescribing Guidelines and Specialist Care

Utilize safe opioid practices pursuant to evolving federal and state regulations and expert guidelines on treating pain and prescribing opioids

Identify patients who may warrant referral to specialist care

Module 6: Opioid Misuse and Opioid Use Disorder

Counsel patients and caregivers about the safe use of opioid analgesics, including proper storage and disposal

Outline evidence-based strategies for treatment of opioid use disorder (OUD)

 

 

ACCREDITATION STATEMENTS

  

Accreditation Council for Continuing Medical Education (ACCME) Accreditation Statement

MedicusCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

ACCME Designation Statement

MedicusCME designates this Other activity (collaborative, small group social-learning model) for a maximum of 4.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center (ANCC) and the Ohio Nurses Association.

 

This nursing continuing professional development activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)

 

 

ACCREDITATION  COUNCIL FOR PHARMACY EDUCATION

Universal Activity Number (UAN) for pharmacists: 0215-9999-011-H08-P

Pharmacist attendees will obtain 4.5 hours of CE credit.

 

Activity ID: 2020-0000000317 has received ONA approval for 4.50 contact hours

Approval valid through     06/23/2022 

 

HOW TO CLAIM CREDIT

In order to receive AMA PRA Category 1 credit and ANCC contact hours, participants must do the following:
 

• Read the learning objectives and faculty disclosures.
• Participate in the activity, review course content and learning strategies, resources and support materials provided
• Complete the post-test and activity evaluation.
• You must score with an 75% or higher on the post-test to receive credit for this activity

 

COURSE FORMAT/MEDIUM: Internet Activity (Enduring Material)

 

ESTIMATED TIME TO COMPLETE ACTIVITY: 4.5 hours

Because this continuing education activity is made available to learners in a small group learning model, the following suggestions indicating the estimated time that each component was designed to require have been provided to assist learners (who did not participate in the entire activity) in determining the appropriate partial credit to claim. These are offered only as a guide. Learners should claim only the credit commensurate with the extent of their participation in the activity.

 

Baseline Self Assessment - 0.5 credit

Self Study Module #1 - 0.25 credit

Self Study Module #2 - 0.25 credit

Self Study Module #3 - 0.5 credit

Self Study Module #4 - 0.5 credit

Self Study Module #5 - 0.25 credit

Self Study Module #6 - 0.25 credit

Final Self Assessment - 0.5 credit

Live Group Discussion - 0.75 credit

Group Task – 0.75

 

 

ACKNOWLEDGEMENTS
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see

https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).

 

MedicusCME represents that the Program shall conform to and comply with the AMA Ethical Opinions 8.061 (Gifts to Physicians from Industry) and 9.011 (Ethical Issues in CME) and the Pharmaceutical Research and Manufacturers Association Code on Interactions with Healthcare Professionals.

 

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

FACULTY CONTENT TEAM

Jade Malcho, MD
Clinical Instructor, Emergency Medicine, Addiction Medicine
University of Rochester School of Medicine & Dentistry
Rochester, New York
Medical Director, Addiction Medicine, Delphi Rise
Rochester, New York

 

Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM

(unpaid consultant)

 

Chief of Medical Services, New York State Office of Addiction Services and Supports

Past Medical Director of an academic center-based OTP in the South Bronx before working for nearly a decade for a large FQHC in the Hudson Valley; created and grew a MAT program for OUD and AUD to 10 sites and 1500 patients

Until June 2020, Vice-Chair of the Substance Use Guidelines Committee for the HIV Clinical Practice Guidelines (a collaboration with Johns Hopkins University)

Co-Chair, Office of Drug User Health’s NYS Buprenorphine Advisory Group

Recipient, NYS Department of Health Commissioner’s Special Recognition Award for contributions to drug user health in New York State, December 2018.

National Board of Directors/Regional Director representing New York State, American Society of Addiction Medication

 

Ross W. Sullivan, MD

Director, State University of New York Upstate Emergency Opioid Bridge Clinic
SUNY Upstate Medical University
Medical Director, Helio Health – Behavioral Health
Syracuse, New York

 

Frank North, PharmD, MPA

Assistant Professor, Law & Ethics
Texas A&M University Irma Lerma Rangel College of Pharmacy
College Station, Texas
Adjunct Professor, Houston Community College System, Federal and State Government
Houston, Texas

Clinical Pharmacist Entrepreneur
The Rowe Network
Texas and Washington, DC

 

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

Director of Addiction, Toxicology at University of Rochester Medical Center (URMC) Director of the Addiction Medicine Fellowship Department of Emergency Medicine -URMC

Associate Professor of Emergency Medicine, Strong Memorial Hospital and the University of Rochester, Rochester, New York

New York Society of Addiction Medicine, President

American College of Medical Toxicology (ACMT), Board

American Society of Addiction Medicine, Board

Rochester, New York

 

EXPERT INDEPENDENT REVIEWER

Tyler S. Oesterle, MD, MPH

Medical Director, Fountain Centers Chemical Dependency Treatment Program

Department of Psychiatry and Psychology, Mayo Health System

Assistant Professor of Psychiatry, Mayo Clinic College of Medicine and Science

Rochester, Minnesota

 

PLANNERS

Timothy J. Wiegand, MD

Director of Addiction, Toxicology at University of Rochester Medical Center (URMC)

 

Steven Haimowitz, MD

President, RealCME

 

Frank North, PharmD, MPA

Assistant Professor, Law & Ethics

Texas A&M University Irma Lerma Rangel College of Pharmacy

 

Carol Pashman, MS, RN

President, MedicusCME

 

MEDICAL WRITER

Margo Embree Fisher

 

MedicusCME’s POLICY ON CONFLICT OF INTEREST

It is the policy of MedicusCME to identify and resolve any potential conflicts of interest of anyone who may be in a position to influence or control the content of education activity, to assure balance, independence, objectivity, and scientific rigor in all of its accredited activities. All faculty and planners are expected to disclose all financial relationships with a commercial interest within the past twelve months.

 

CONFLICT OF INTEREST DISCLOSURES

Dr. Timothy Wiegand acknowledges receipt of honoraria from Braeburn Pharmaceuticals and Titan Pharmaceuticals for his role as consultant.

All other members of the Faculty Content Team, authors and planners, and the Expert Content Reviewer of this accredited activity deny any personal or financial relationships with ACCME-defined ineligible companies that may constitute any real or perceived conflict of interest.

 

All financial relationships are thoroughly vetted and mitigated according to MedicusCME policy.